October 16, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Tolebrutinib found to show benefits for up to 3 years Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS), according to new data from the long-term safety (LTS) extension of a Phase 2b trial. The data…
November 4, 2022 News by Lindsey Shapiro, PhD #ECTRIMS2022 ā 3-year Data Show Evobrutinib Safely Lowers Relapses Long-term use of the investigational BTK inhibitor evobrutinib among people with relapsing forms of multiple sclerosis (MS) continues to maintain MS relapse rates, and keep MRI lesion activity low. That’s according to up to 3.5 years of data from a Phase 2 trial (NCT02975349) and its open-label…
October 28, 2022 News by Marta Figueiredo, PhD #ECTRIMS2022 ā Long-term Gilenya Reduces Pediatric Relapses Long-term treatment withĀ Gilenya (fingolimod) continues to be safe and lower the rate of relapses in children and adolescents with multiple sclerosis (MS) more than Avonex (interferon beta-1a) does. Thatās according to up to six years of data from the ongoing PARADIGMS Phase 3 trial (NCT01892722), wherein…
August 30, 2022 News by Marta Figueiredo, PhD Long-term Ponvory Treatment Safe, Effective in RRMS, Trial Data Show Long-term treatment with Ponvory (ponesimod) safely and effectively reduces the rate of relapses, slows disability worsening, and prevents brain volume decline in adults with relapsing-remitting multiple sclerosis (RRMS). Thatās according to eight years of data from patients enrolled in a now-completed Phase 2 clinical trial (NCT01006265)Ā and its…
June 30, 2022 News by Marisa Wexler, MS Long-term Zeposia May Help Cognitive Function in Patients, Data Show Long-term treatment with Zeposia (ozanimod) stabilizes or even improves cognitive function in adults with relapsing forms of multiple sclerosis (MS), particularly among those with greater brain volumes. Thatās according to five years of data from the completed SUNBEAM Phase 3 clinical trial (NCT02294058) and the ongoing…
April 28, 2022 News by Marisa Wexler, MS #AAN2022 ā Tolebrutinib Reduces Brain Damage Up to 1.5 Years in Trial Long-term treatment with tolebrutinib significantly reduced signs of disease-related brain damage in people with relapsing multiple sclerosis (MS), according to new data from a Phase 2 clinical trial and its extension study. Specifically, the investigational oral therapy was found to keep the number of inflamed brain lesions…